Daiichi Sankyo Company, Limited

Shinji Matuura

Nobuyuki Suzuki

Masahiro Ikeda

Hitoshi Ohki

Yoshihiro Shibata

Masahiro Ota

Yasusi Ueda

Toshiyuki Nakanishi

Tooru Okayama

Tatsuya Nakamura

Hitoshi Sato

Tatsuya Yamaguchi

Shigeru Noguchi

Takahiro Aoki

Yutaka Kitagawa

Tsuyoshi Ueda

Hisaki Kajino

Kohei Sakanishi

Keijiro Kobayashi

Tadahiro Takeda

Tomoyuki Nagai

Takashi Kouko

Fumikatsu Kondo

Kei Kurahashi

Yohei Yamane

Crystals of the compound represented by formula (1), a method for the production thereof, and a method for producing an antibody-drug conjugate using the crystals.

Method for producing antibody-drug conjugate

To provide a hydrochloride of a tricyclic pyrazolopyrimidine compound inhibiting the effect of HSP90 and a crystal thereof. The present invention provides a hydrochloride of 2-{4-amino-2-[(3-chloro-4-methoxy-5-methylpyridin-2-yl)methyl]-2,7-dihydro-6-thia-1,2,3,5-tetraazabenzo[cd]azulen-8-yl}-N-methylacetamide which inhibits the ATPase activity of HSP90 and which has antitumor activity, a crystal thereof, a medicament comprising the same, an anticancer agent comprising the same, and the like.

Crystal of tricyclic pyrazolopyrimidine derivative

A pyrazolopyrimidine compound represented by formula (1) that inhibits the function of HSP90 as a chaperone protein and that has antitumor activity, a medicament comprising a compound represented by formula (1), a pharmaceutical composition comprising a compound represented by formula (1), and a method for treating cancer using a compound represented by formula (1). 

Tricyclic pyrazolopyrimidine derivatives

Growing community of inventors

Kanagawa, Japan

Shinji Matuura